검색 열기

통합검색
모바일메뉴 열기
 

교수진소개

임정연 프로필 사진
  • 성명

    임정연 교수

  • 전공

    임상병리학(임상화학)

  • 최종학위

    가톨릭대학교 이학박사

  • 연구실

    인제대학교 성산관 409호

  • 연락처

    055-320-3482

  • 이메일

    limjy@inje.ac.kr

학력

- (학사) 연세대학교 임상병리학과
- (석사) 가톨릭대학교 의생명‧건강과학과
- (박사) 가톨릭대학교 의생명‧건강과학과

교육 및 연구경력

- 2023.03 ~ 현재 Frontiers in Immunology [IF 8.786] (리뷰 에디터)
- 2021.09 ~ 현재 인제대학교 임상병리학과 (조교수)
- 2017.05 ~ 2021.06 Icahn School of Medicine at Mount Sinai, New York, USA (박사후 연구원)
- 2013.10 ~ 2013.11 The Tokyo University, Japan (방문연구원)

기타 및 학술관련 경력

- 정회원, The American Association of Immunologists
- 정회원, 대한혈액학회 
- 정회원, 대한조혈모세포이식학회 
- 정회원, 대한실험혈액학회 
- 정회원, 대한면역학회 
- 정회원, International Society of Cell Therapy

연구 관심 분야

- 자가면역질환 및 면역질환의 염증성분자에 의한 병인 연구
- 신약 및 세포치료제 개발을 위한 전임상 연구

강의 분야

- 임상화학, 임상화학 및 실험, 뇨화학 및 실험, 고급임상기기학
- 분자면역학
- 캡스톤디자인

저서 및 주요 논문

논문
  1. Yang CE, Kim SB, Jeong Y, *Lim JY. Synergistic Inhibition of Burkitt’s Lymphoma with Combined Ibrutinib and Lapatinib Treatment. Korean J Clin Lab Sci. 2023;55(4):1-00. *Corresponding
  2. Jeong Y, Kim SB, Yang CE, Yu MS, Choi WS, *Jeon Y, *Lim JY. Overcoming the therapeutic imitations of EZH2 inhibitors n Burkitt’s lymphoma: a comprehensive study on the combined effects of MS1943 and Ibrutinib. Frontiers in Oncology. 2023 11:13:1252658. DOI: 10.3389/fonc.2023.1252658 *Corresponding
  3. Kim SB, Yang CE, Jeong Y, Yu M, Choi WS, *Lim JY, *Jeon Y. Dual Targeting of EZH2 Degradation and EGFR/HER2 Inhibition for Enhanced Efficacy against Burkitt’s Lymphoma. Cancers. 2023 15(18), 4472; https://doi.org/10.3390/cancers15184472 *Corresponding
  4. +Jeon Y, +Lim JY, Im KI, Lim N, Cho SG. BAFF blockade attenuates acute graft-versus-host disease directly via the dual regulation of T- and B- cell homostasis. 2022.12.06. Frontiers in Immunology. +These authors have contributed equally to this work
  5. Lim JY, Duttke S. H, Baker T. S., Lee J, Gambino K. J., Venturini N. J, Jessica Sook Yuin Ho J. S. Y., Zheng S., Fstkchyan Y., Pillai V. Fajgenbaum D. C., Marazzi I., Benner C., Byun M. DNMT3A haploinsufficiency causes dichotomous DNA methylation defects at enhancers in mature human immune cells. 2021 Jul 5;218(7):e20202733. Journal of Experimental Medicine.
  6. Song Y, Lim JY, Lim T, Im KI, Kim N, Nam YS, Jeon YW, Shin JC, Ko HS, Park IY, Cho SG. Human mesenchymal stem cells derived from umbilical cord and bone marrow exert immunomodulatory effects in different mechanisms. World Journal of Stem Cells. 2020 September 26; 12(9): 1032-1049.
  7. Im KI, Nam YS, Kim N, Song Y, ES Lee, Lim JY, Jeon YW, Cho SG. Regulation of HMGB1 release protects chemoradiotherapy-associated mucositis. Mucosal Immunology. 2019 Jan 15 doi: 10.1038/s41385-019-0132-x.
  8. Baker TS, Gambino KJ, Schriefer L, Lim JY, Steinberg KM, Fajgenbaum DC, Martín García-Sancho A, Byun M. A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease. Blood Advances. 2018 Nov 13;2(21):2959-2963.
  9. Jeon YW, Lim JY, Im KI, Kim N, Nam YS, Song YJ, Cho SG. Enhancement of Graft-versus-Host Disease Control Efficacy by Adoptive Transfer of Type 1-Regulatory T Cells in Bone Marrow Transplant Model. Stem Cells Dev. 2018 Nov 1. doi: 10.1089/scd.2018.0113.
  10. Kim N, Nam YS, Im KI, Lim JY, Jeon YW, Song Y, Lee JW, Cho SG. Robust Production of cytomegalovirus pp65-Specific T Cells Using a Fully Automated IFN-γ Cytokine Capture System. Transfusion Medicine Hemotheraopy. 2018 Jan;45(1):13-22.
  11. Lim JY, Im KI, Song YJ, Kim N, Nam YS, Jeon YW, Cho SG. Third-party regulatory T cells prevent murine acute graft-versus-host disease. The Korean Journal of Internal Medicine. 2017 Oct 19. doi: 10.3904/kjim.2016.319..
  12. Lim JY, Im KI, Lee ES, Kim N, Nam YS, Jeon YW, Cho SG. Enhanced immunoregulation of mesenchymal stem cells by IL-10-producing type 1 regulatory T cells in collagen-induced arthritis. Scientific Reports. 2016 Jun 1;6:26851.


그 외

특허
  1. 특허출원(No. 10-2023-0184820): Therapeutic agent of T cell lymphoma comprising miRNA500 inhibitor
  2. 특허출원(No. 10-2023-0177278): Combination of PROTAC-based EZH2 degrader and JAK3 inhibitor for treating for CTCL model 
  3. 특허출원(No. 10-2023-0177312): The combined therapeutic effect of METTL3 inhibitor and EZH2 degrader in hematologic malignancy 
  4. 특허출원(No. 10-2023-0177297): Pharmaceutical composition for preventinn or treatment of lymphoma and leukemia, comprising BTK degrader and METTL3 inhibitor
  5. 특허출원(No. 10-2023-0057801): A pharmaceutical composition for preventing or treating hematologic malignancy comprising a BTK degrader and a Bcl-6 degrader
  6. 특허출원(No. 10-2022-0154550, PCT/KR2023/018176): Pharmaceutical composition for the prevention or treatment of lymphoma, comprising EZH2 degrader and BTK inhibitor
  7. 특허출원(No. 10-2022-0154558, PCT/KR2023/018173): Pharmaceutical composition for the prevention or treatment of lymphoma, comprising EZH2 degrader and anti-PD-1 antibody
  8. 특허등록(No. 101865040000): Use of mesenchymal stem cell having enhanced capability of producing immunoregulatory factor.
  9. 특허등록(No. 10186794200000): Method for enrichment and expansion of virus antigen-specific CIK cells. 
  10. 특허등록(No.101518370000): Compositions for induction of IL-10 producing regulatory T cell differentiation.
  11. 특허등록(No.1017183800000): Pharmaceutical composition comprising NecroX for preventing or treating mucositis.
  12. 특허등록(No.1019410040000): Pharmaceutical composition for suppressing immune response by inducing differentiation to regulatory T cell and promoting proliferation.
  13. 특허등록(No.1015785910000): Cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory T cells as active ingredients.
  14. 특허등록(No.1014328810000): Cytoprotection composition for toxicity suppression of natural killer cells including retinal or retinoic acid.
  15. 특허등록(No.1017053780000): Composition containing mesenchymal stem cells and an IL-21 inhibitor for preventing or treating graft-versus-host disease.
  16. 특허등록(No.1016945540000) Cell therapeutic composition containing a natural killer cell inhibitor and mesenchymal stem cells for preventing or treating graft-versus-host disease.
  17. 특허등록(No.1013511210000): Composition for preventing or treating immunological rejection disease including IL-27. 

수상실적
- 2023.11 우수 포스터 발표상, 주최: 대한의생명과학회
- 2023.10 우수심사자상, 주최: 대한임상병리사협회, 대한임상검사과학회
- 2023.06 학술상, 주최: 대한임상병리학과 교수협의회
- 2017.02 학술상(박사학위), 주최: 가톨릭대학교
- 2015.08 Young Investigator Award, 주최: Asian Cellular Therapy   Organization
- 2015.02 우수 연제상, 주최: 대한조혈모세포이식학회
- 2015.02 우수상, 주최: BK21 플러스 컨버전스헬스케어사업단
- 2013.10 Travel Grant Award, 주최: The Japanese Society of Hematology
- 2013.08 학술상(석사학위), 주최: 가톨릭대학교